Cellectar Biosciences, Inc.
Fractionated Dosing of a Phospholipid Ether Analog for the Treatment of Cancer
Last updated:
Abstract:
Disclosed herein is a fractionated dosing regimen of .sup.131I-labeled 18-(p-iodo-phenyl)octadecyl phosphocholine for the treatment of cancer.
Status:
Application
Type:
Utility
Filling date:
10 Apr 2019
Issue date:
15 Apr 2021